Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

The majority of deaths from MBC are in patients with hormone receptor (HR) positive, HER2 negative disease. Endocrine therapy (ET) remains the backbone of treatment in these cases, improving survival and quality of life. However, treatment can lose effectiveness due to primary or acquired endocrine...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballinger, Tarah J., Meier, Jason B., Jansen, Valerie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095972/
https://www.ncbi.nlm.nih.gov/pubmed/30148117
http://dx.doi.org/10.3389/fonc.2018.00308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095972/
https://www.ncbi.nlm.nih.gov/pubmed/30148117
http://dx.doi.org/10.3389/fonc.2018.00308

Ejemplares similares